A controlled clinical trial of the efficacy of the hepatitis B vaccine (heptavax B): A final report
Wolf Szmuness, Cladd E. Stevens, Edith A. Zang, Edward J. Harley, Aaron Kellner – 1 September 1981 – A controlled, randomized, double‐blind trial in 1,083 homosexual men from New York confirmed that a highly purified, formalin‐inactivated vaccine against hepatitis B prepared from HBsAg positive plasma, is safe immunogenic, and highly efficacious. Over 95% of vaccinated subjects developed antibody against the surface antigen. Vaccine‐induced antibody persisted for the entire 24‐month follow‐up period.